Background illustration for clinical trials search

Multiple Sclerosis Clinical Trials

Browse 937 multiple sclerosis clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

for
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Location: Guilford CT, North Haven CT, New Haven CT, Derby CT,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06465316

Phase1, Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

for
Relapsed or Refractory Multiple Myeloma,
Location: New York NY, Philadelphia PA, Charlotte NC, Houston TX,
Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT05652335

Phase1, Recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

for
Monoclonal Gammopathy of Undetermined Significance (MGUS),
Location: Boston MA, Stony Brook NY, New York NY, Philadelphia PA,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06140524

Phase2, Recruiting

ATRA and Carfilzomib in Plasma Cell Myeloma Patients

for
Multiple Myeloma
Location: Houston TX
Sponsor: The Methodist Hospital Research Institute

Sex: All

Age: 18+

Code: NCT06536413

Phase1, Phase2, Recruiting

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

for
Multiple Myeloma, Autologous Stem Cell Transplantation
Location: Augusta GA
Sponsor: Augusta University

Sex: All

Age: 18+

Code: NCT06588413

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

for
Relapsed/Refractory Multiple Myeloma
Location: Boston MA, Stony Brook NY, New York NY,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT05850234

Phase1, Phase2, Recruiting

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: Oklahoma City OK
Sponsor: Sorrento Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05007418

Phase1, Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: Boston MA, New York NY, Hackensack NJ, Buffalo NY,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All

Age: 18+

Code: NCT06121843

Phase1, Recruiting

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: New York NY, Tampa FL, Columbus OH, Atlanta GA,
Sponsor: Regeneron Pharmaceuticals

Sex: All

Age: 18+

Code: NCT03761108

Phase1, Phase2, Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

for
Relapsed or Refractory Multiple Myeloma (RRMM)
Location: Halifax, Boston MA, New York NY, Montreal,
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All

Age: 18+

Code: NCT06615479

Phase3, Recruiting

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

for
Multiple Myeloma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18 - 70+

Code: NCT05776979

Phase2, Recruiting

18F-Fluciclovine PET/CT in Multiple Myeloma

for
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM),
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT06103838

Phase2, Recruiting

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

for
Multiple Myeloma
Location: Detroit MI, Lansing MI
Sponsor: Barbara Ann Karmanos Cancer Institute

Sex: All

Age: 18+

Code: NCT06107738

Phase2, Recruiting

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

for
Smoldering Multiple Myeloma
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: All

Age: 18+

Code: NCT06212323

Recruiting

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

for
Multiple Myeloma
Location: Jacksonville FL, Encinitas CA, Alhambra CA,
Sponsor: Oncotherapeutics

Sex: All

Age: 18+

Code: NCT03110822

Phase1, Recruiting

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

for
Multiple Myeloma, Monoclonal Gammopathy of Renal Significance
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT06083922

Phase2, Recruiting

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

for
Multiple Myeloma, Renal Failure
Location: Augusta GA
Sponsor: Augusta University

Sex: All

Age: 18 - 70+

Code: NCT06142396

Early_phase1, Recruiting

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

for
Multiple Myeloma
Location: Boston MA, Durham NC, Chapel Hill NC, Cincinnati OH,
Sponsor: Prolexys Pharmaceuticals

Sex: All

Age: 18+

Code: NCT01695590

Phase1, Phase2, Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

for
Multiple Myeloma, Plasma Cell Disorder
Location: New York NY, Atlanta GA, Omaha NE, Houston TX
Sponsor: Heidelberg Pharma AG

Sex: All

Age: 18+

Code: NCT04879043

Phase1, Phase2, Recruiting

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

for
Multiple Myeloma
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT06048250

Phase1, Recruiting

What is multiple sclerosis?

In MS, the immune system attacks myelin, the insulation around nerve fibers in the brain and spinal cord. Damaged spots, called lesions, slow or block nerve signals, which is why symptoms range from fatigue and numbness to vision problems and trouble walking. Symptoms and pace differ so much between people that MS is often called a disease with a thousand faces. It is not contagious, and it is not directly inherited. Worldwide about 2.9 million people live with MS, someone is diagnosed roughly every five minutes, and the average age at diagnosis is 32.

Research in this field carries one of the most striking findings in modern medicine: a 2022 study of more than 10 million US military members found that infection with the Epstein Barr virus, the common virus behind mononucleosis, raises MS risk 32 times, making it the leading suspected cause. Meanwhile treatment keeps expanding, with more than 20 approved disease modifying therapies, though the progressive forms still have almost none.

The types of MS, and why they matter for trials

Types of multiple sclerosis clinical trials

Who can participate in MS trials?

Do MS trial participants get paid?

How to enroll in a clinical trial for multiple sclerosis